Showing 5781-5790 of 9807 results for "".
- Aspiring Physician with Psoriasis Among AbbVie Scholarship Recipientshttps://practicaldermatology.com/news/aspiring-dermatologist-with-psoriasis-among-abbvie-scholarship-recipients/2461201/AbbVie has awarded 45 scholarships as part of its 2022-2023 AbbVie Immunology Scholarship program. The program, which provides financial support to students living with chronic, immune-mediated diseases pursuing higher education in the United States, received more than 1,000 applic
- Eucerin Launches Skin-focused Sun Care Line in the UShttps://practicaldermatology.com/news/eucerin-launches-skin-focused-sun-care-line-in-the-us/2461196/Eucerin is expanding into the US sun protection market with its new Eucerin Sun line. Developed with dermatologists and consisting of seven products across face and body, Eucerin Sun is formulated with a five antioxidants to go beyond sun protection and help promote healthy-looking
- Murad Joins Forces with Sesame to Offer Skin Care Consults with Dermatologists, Primary Care Doctorshttps://practicaldermatology.com/news/murad-joins-forces-with-sesame-to-offer-skin-care-consults-with-dermatologists-primary-care-doctors/2461194/Murad is partnering with Sesame to introduce skin consultations with board-certified dermatologists and primary care clinicians. <
- Ophthalmologist Ashley Brissette, MD Launches Eye Area Skincare Linehttps://practicaldermatology.com/news/ophthalmologist-ashley-brissette-md-launches-eye-area-skincare-line/2461193/Daily Practice, the new eye care line by ophthalmologist Ashley Brissette, MD, has launched with a hero product—Eye Revive. Having worked as an ophthalmologist for six years, New York City-based Dr. Brissette says she recognized a growing trend of
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u
- Indoor Tanning Ban Could Slash Melanoma Deathshttps://practicaldermatology.com/news/indoor-tanning-ban-could-slash-melanoma-deaths/2461190/An indoor tanning ban in England would reduce melanoma deaths, according to a study by University of Manchester researchers. By tracking the projected impact on the 618,000 18-year-olds living in England in 2019, the research team showed that a ban on indoor tanning would resu
- Handheld Device May Painlessly Identify Skin Cancershttps://practicaldermatology.com/news/handheld-device-may-painlessly-identify-skin-cancers/2461188/Researchers at Stevens Institute of Technology are developing a low-cost handheld device that could cut the rate of unnecessary biopsies in half and give dermatologists and other frontline physicians easy access to laboratory-grade cancer diagnostics. “We aren’t trying
- Curél Gives Back: Skincare Brand Supports Nurseshttps://practicaldermatology.com/news/curel-gives-back-skincare-brand-supports-nurses/2461187/Through Curél Cares, Curél will be donating to the American Nurses Foundation and treating several highly deserving nurses to an all-expenses-paid pampering trip to New York City. In addition, Curél will also sponsor the half-day American Nurses Associati
- Stratpharma Inc. USA Names Michael Flowers President of North American Commercial Operationshttps://practicaldermatology.com/news/stratpharma-inc-usa-names-michael-flowers-president-of-north-american-commercial-operations/2461185/Michael Flowers is now President of North America Commercial Operations for Stratpharma Inc. in the United States. Mr. Flowers joins Stratpharma from WSI, where he served as Chief Commercial Officer. Stratpharma Inc. USA is the US subsidi
- ASLMS: CellFX from Pulse Offers Durable Clearance of SH Lesionshttps://practicaldermatology.com/news/aslms-cellfx-from-pulse-offers-durable-clearance-of-sh-lesions/2461183/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022